The Global Resource For Connecting Buyers and Sellers

Prometic’s PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized

Clinical trial design confirmed during FDA Type C meeting held on January 3, 2018
Simplified patient entry criteria to include IPF patients whether on background standard of care (i.e. nintedanib) or not
Primary endpoint analysis to be stratified on background therapy…